Contributions
Abstract: P358
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Background: Differential treatment allocation may impact on clinical phenotype in MS and in turn upon quality of life (QoL).
Objectives: (a) Investigate the association between disease-modifying drugs (DMDs) use and relapse frequency, disability, clinically significant fatigue, and physical & mental health-related QoL among participants with MS residing in Australia and New Zealand (NZ); (b) assess whether these associations differed significantly between Australia & NZ.
Methods: Disability and fatigue were measured by PDDS and FSS, respectively. QoL was assessed by MSQOL-54. Associations were assessed by binomial and multinomial logistic regression, as appropriate, adjusted for relevant covariates. Multivariable models were adjusted for demographic and clinical covariates, as appropriate.
Results: 837 participants (627 from Australia; 210 from NZ) using DMDs were identified from an online cohort of people with MS. First- and second-generation DMD use was associated with significantly higher adjusted-odds of fatigue and disability, though not with 12-month relapse number. DMD use was not associated with physical or mental QoL. The association of first-generation DMD use with moderate disability significantly differed between nations, such that treatment was associated with lower odds in Australia but not in NZ; a similar difference was found for severe disability but did not reach significance. No differences were seen in the DMD association with relapse number, nor with fatigue or QoL, between Australia & NZ.
Conclusion: The differential treatment allocation associations in NZ are evident in the DMD-disability association, but there is no evidence that this treatment regime has negative associations with fatigue, mood, or QoL.
Disclosure: The study was funded by the Bloom Foundation, Wal Pisciotta, and the Horne Family Charitable Trust. CM is funded by an Early Career Fellowship from the National Health and Medical Research Council (ID 1120014).
AZZP: nothing to disclose.
AMDL: nothing to disclose.
GAJ receives royalties for his books, Overcoming Multiple Sclerosis and Recovering from Multiple Sclerosis, and has received remuneration for conducting lifestyle educational workshops for people with MS.
CRB: nothing to disclose.
EO´K: nothing to disclose.
SN has received remuneration for conducting lifestyle educational workshops for people with MS.
KLT has received remuneration for conducting lifestyle educational workshops for people with MS.
WB: nothing to disclose.
SSJ: nothing to disclose.
TJW: nothing to disclose.
Abstract: P358
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Background: Differential treatment allocation may impact on clinical phenotype in MS and in turn upon quality of life (QoL).
Objectives: (a) Investigate the association between disease-modifying drugs (DMDs) use and relapse frequency, disability, clinically significant fatigue, and physical & mental health-related QoL among participants with MS residing in Australia and New Zealand (NZ); (b) assess whether these associations differed significantly between Australia & NZ.
Methods: Disability and fatigue were measured by PDDS and FSS, respectively. QoL was assessed by MSQOL-54. Associations were assessed by binomial and multinomial logistic regression, as appropriate, adjusted for relevant covariates. Multivariable models were adjusted for demographic and clinical covariates, as appropriate.
Results: 837 participants (627 from Australia; 210 from NZ) using DMDs were identified from an online cohort of people with MS. First- and second-generation DMD use was associated with significantly higher adjusted-odds of fatigue and disability, though not with 12-month relapse number. DMD use was not associated with physical or mental QoL. The association of first-generation DMD use with moderate disability significantly differed between nations, such that treatment was associated with lower odds in Australia but not in NZ; a similar difference was found for severe disability but did not reach significance. No differences were seen in the DMD association with relapse number, nor with fatigue or QoL, between Australia & NZ.
Conclusion: The differential treatment allocation associations in NZ are evident in the DMD-disability association, but there is no evidence that this treatment regime has negative associations with fatigue, mood, or QoL.
Disclosure: The study was funded by the Bloom Foundation, Wal Pisciotta, and the Horne Family Charitable Trust. CM is funded by an Early Career Fellowship from the National Health and Medical Research Council (ID 1120014).
AZZP: nothing to disclose.
AMDL: nothing to disclose.
GAJ receives royalties for his books, Overcoming Multiple Sclerosis and Recovering from Multiple Sclerosis, and has received remuneration for conducting lifestyle educational workshops for people with MS.
CRB: nothing to disclose.
EO´K: nothing to disclose.
SN has received remuneration for conducting lifestyle educational workshops for people with MS.
KLT has received remuneration for conducting lifestyle educational workshops for people with MS.
WB: nothing to disclose.
SSJ: nothing to disclose.
TJW: nothing to disclose.